These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 26335915

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G.
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW.
    Vaccine; 2013 Sep 13; 31(40):4389-97. PubMed ID: 23856331
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.
    Johnson C, Hohenboken M, Poling T, Jaehnig P, Kanesa-Thasan N.
    J Infect Dis; 2015 Jul 01; 212(1):72-80. PubMed ID: 25538277
    [Abstract] [Full Text] [Related]

  • 27. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
    Bencharitiwong R, Leonard S, Tsai T, Nowak-Węgrzyn A.
    Hum Vaccin Immunother; 2012 Jul 01; 8(7):863-5. PubMed ID: 22777093
    [Abstract] [Full Text] [Related]

  • 28. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.
    Song JY, Cheong HJ, Tsai TF, Chang HA, Choi MJ, Jeon JH, Kang SH, Jeong EJ, Noh JY, Kim WJ.
    Vaccine; 2015 Aug 26; 33(36):4647-52. PubMed ID: 25980426
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children - A systematic review and a meta-analysis.
    Patel MM, Davis W, Beacham L, Spencer S, Campbell AP, Lafond K, Rolfes M, Levine MZ, Azziz-Baumgartner E, Thompson MG, Fry AM.
    Vaccine; 2020 Jan 16; 38(3):608-619. PubMed ID: 31735505
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, Edelman J, Smolenov I.
    Vaccine; 2020 Jan 10; 38(2):242-250. PubMed ID: 31635976
    [Abstract] [Full Text] [Related]

  • 35. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ.
    J Med Virol; 2013 Sep 10; 85(9):1591-7. PubMed ID: 23852684
    [Abstract] [Full Text] [Related]

  • 36. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N.
    J Infect Dev Ctries; 2014 Sep 12; 8(9):1160-8. PubMed ID: 25212080
    [Abstract] [Full Text] [Related]

  • 37. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 38. Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.
    Gillard P, Giet D, Heijmans S, Dramé M, Walravens K, Roman F.
    Trials; 2014 Oct 29; 15():419. PubMed ID: 25354581
    [Abstract] [Full Text] [Related]

  • 39. A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age.
    Otten G, Matassa V, Ciarlet M, Leav B.
    Vaccine; 2020 Jan 16; 38(3):578-587. PubMed ID: 31679865
    [Abstract] [Full Text] [Related]

  • 40. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR, DMID 13-0032 H7N9 Vaccine Study Group.
    JAMA; 2014 Oct 08; 312(14):1409-19. PubMed ID: 25291577
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.